DALT
Chemical compound
From Wikipedia, the free encyclopedia
Diallyltryptamine (DALT), also known as N,N-diallyltryptamine, is a tryptamine derivative which has been identified as a designer drug.[2][3]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | N,N-Diallyltryptamine; DALT; DAT |
| Routes of administration | Oral, intramuscular injection[1] |
| Drug class | Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H20N2 |
| Molar mass | 240.350 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Use and effects
According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), the dose of DALT is greater than 40 mg orally and its duration is unknown.[1] Its effects were not described.[1] Per Stephen Szara and colleagues in much earlier publications however, DALT and other extended N,N-dialkyltryptamines produce similar effects to dimethyltryptamine (DMT) but are longer-lasting, with durations of up to 3 hours.[1][4][5]
Interactions
Pharmacology
Pharmacodynamics
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 100 |
| 5-HT1B | >10,000 |
| 5-HT1D | 689 |
| 5-HT1E | 378 |
| 5-HT1F | ND |
| 5-HT2A | 701 |
| 5-HT2B | 61 |
| 5-HT2C | 385 |
| 5-HT3 | >10,000 |
| 5-HT4 | ND |
| 5-HT5A | >10,000 |
| 5-HT6 | 1,718 |
| 5-HT7 | >10,000 |
| α1A | 1,663 |
| α1B | 1,369 |
| α1D | >10,000 |
| α2A | 124 |
| α2B | 305 |
| α2C | 901 |
| β1–β3 | >10,000 |
| D1, D2 | >10,000 |
| D3 | 672 |
| D4, D5 | >10,000 |
| H1 | 127 |
| H2–H4 | >10,000 |
| M1–M5 | >10,000 |
| I1 | ND |
| σ1 | 101 (rat) |
| σ2 | 356 (rat) |
| TAAR1 | ND |
| MOR, DOR | >10,000 |
| KOR | 2,477 |
| SERT | 150 (Ki) |
| NET | 1,121 (Ki) |
| DAT | 1,406 (Ki) |
| Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs:[6][7][8][9] | |
The receptor interactions of DALT have been studied.[6][7][8][9] The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[10]
Chemistry
DALT has been used as an intermediate in the preparation of radiolabeled diethyltryptamine (DET).[11]
Synthesis
The chemical synthesis of DALT has been described.[1]
Analogues
Analogues of DALT include 4-HO-DALT, 4-AcO-DALT, 5-MeO-DALT, methylallyltryptamine (MALT), propylallyltryptamine (PALT), and isopropylallyltryptamine (iPALT), among others.[1]
History
DALT was first described in the scientific literature by Stephen Szara and colleagues by 1962.[4][5]
Society and culture
Legal status
Canada
DALT is not an explicitly nor implicitly controlled substance in Canada as of 2025.[12]
United States
DALT is not an explicitly controlled substance in the United States.[13] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.